Growth arrest by activated BRAF and MEK inhibition in human anaplastic thyroid cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Anaplastic thyroid cancer (ATC) is a rare, aggressive malignancy with a poor prognosis.
• The RAS/RAF/MEK pathway is frequently implicated in cancer progression.

Purpose of the Study:

• To investigate the efficacy of inhibiting the RAS/RAF/MEK pathway in human ATC cell lines.
• To elucidate mechanisms of drug effect and resistance.
• To assess the impact of genetic alterations on treatment response.

Main Methods:

• Utilized four human ATC cell lines with distinct genetic profiles (BRAF, NRAS, PI3KCA mutations).
• Administered dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) individually and in combination.
• Assessed cellular viability, cell cycle arrest (G0/G1), and downstream signaling pathway phosphorylation (MEK/ERK).
• Analyzed vascular endothelial growth factor (VEGF) and SNAI1 mRNA expression as indicators of response and resistance.

Main Results:

• Dabrafenib inhibited viability in BRAF-mutated ATC cells via G0/G1 arrest and MEK/ERK downregulation.
• Trametinib reduced viability across all cell lines by inhibiting ERK phosphorylation.
• RAS-mutated cells showed MEK phosphorylation and VEGF upregulation with dabrafenib, independent of proliferation.
• Combined inhibition demonstrated a cytostatic effect in all cell lines.
• One cell line exhibited resistance to trametinib and combined therapy, with increased SNAI1 mRNA expression.

Conclusions:

• Mutation-selective BRAF and MEK inhibitors exhibit efficacy in human ATC cells in a manner dependent on specific genetic alterations.
• Understanding genetic profiles is crucial for predicting treatment response and resistance in ATC.
• Dual blockade offers a potential therapeutic strategy, but resistance mechanisms require further investigation.